Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Pfizer, J&J, Merck evaluating technologies for Zika vaccine

Pfizer Inc, Johnson and Johnson and Merck & Co Inc said they were evaluating their technologies or existing vaccines for their potential to combat Zika, a rapidly spreading mosquito-borne disease linked to birth defects. A number of drug developers and universities are attempting to produce a vaccine for Zika, which the World Health Organization (WHO) […]

Read More »

Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer Antibody-Drug Conjugates and XMT-1522

– Takeda obtains rights to Mersana’s XMT-1522 outside U.S. and Canada – – Takeda to create additional Fleximer ADCs; Mersana to have a co-development option – – Mersana to receive $40 million upfront, $20 million upon IND clearance and up to $20 million in equity investment – CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Mersana Therapeutics and […]

Read More »

LAM Therapeutics Closes $40M in Financing and Announces Two Clinical-Stage Programs in Rare Diseases and Cancer

LAM Therapeutics Closes $40M in Financing and Announces Two Clinical-Stage Programs in Rare Diseases and Cancer Bringing the Total Raised for the Current Class of 4Catalyzer Companies to a Quarter-Billion Dollars   GUILFORD, CT–(Marketwired – February 03, 2016) – LAM Therapeutics closed a $40 million financing to accelerate the development of therapeutics for the treatment […]

Read More »

Gilead May Take Page Out Pfizer’s Game Plan as Firm Hunts for M&As to Sustain Growth

February 3, 2016By Alex Keown, Breaking News Staff   FOSTER CITY, Calif. – Gilead Sciences (GILD) is atop the hepatitis C market with its blockbuster treatments Harvoni and Sovaldi, with some analysts predicting strong revenue streams for years to come. However, challenger drugs on the hep C market, such as Merck (MRK)’s Zepatier, priced […]

Read More »

GlaxoSmithKline Bets Another $500 Million on Adaptimmune’s Clinical Cancer Program

Adaptimmune (ADAP) And GlaxoSmithKline (GSK) Expand Strategic Immunotherapy Collaboration • Agreement accelerates development of Adaptimmune’s lead T-cell therapy targeting NY-ESO-1 toward pivotal trials • Creates opportunity for up to eight combination studies LONDON, UK, Philadelphia, Pa. and Oxford, UK, February 2, 2016 – Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in the use of T- […]

Read More »

Newly released documents show profit-seeking behind price hikes at Turing, Valeant

A decision by Turing Pharmaceuticals to raise the price of a lifesaving drug by 5,000 percent drove up some patient co-pays to as high as $16,000, according to excerpts of documents that congressional committee members released on Tuesday. The excerpts, which are highlighted in memos released by Democrats on the powerful U.S. House of Representatives […]

Read More »

Sanofi launches hunt for Zika vaccine as disease fears grow

Sanofi has launched a project to develop a vaccine against the Zika virus in the most decisive commitment yet by a major vaccine producer to fight the disease linked to multiple birth defects in Brazil. The French drugmaker said on Tuesday its Sanofi Pasteur vaccines division would use its expertise in developing vaccines for similar […]

Read More »

Africa, Asia vulnerable to spread of Zika virus: WHO

The Zika virus linked to a microcephaly outbreak in Latin America could spread to Africa and Asia, with the world’s highest birth rates, the World Health Organization warned as it launched a global response unit against the new emergency. The WHO on Monday declared an international public health emergency due to Zika’s link to thousands […]

Read More »

Valeant Accused of Hiding Cold Drug Study Results Proving Drug Was No More Effective than a Placebo

A Vancouver, Canada attorney, John Green, has filed class action lawsuits against Laval, Quebec-based Valeant Pharmaceuticals International (VRX). The lawsuits, which were filed in British Columbia in 2012, and another in Saskatchewan, allege that the company’s popular Cold-FX medication for cold and flu is no better than a placebo in treating symptoms. The lawsuit cites […]

Read More »

As Sanofi Restructures, Merck & Co. Joint Vaccines Venture Might End

Unidentified sources, reported BloombergBusiness yesterday, say that Paris-based Sanofi (SNY) and Kenilworth, NJ-based Merck & Co. (MRK) are discussing ending its vaccines joint venture.   The joint venture, Sanofi Pasteur MSD, reported approximately $330 million in revenues for the first half of 2015, and supplies about 50 percent of Europe’s flu vaccines. In Europe, it […]

Read More »

Carbylan Therapeutics Ostearthrtis Drug Gets Half the Job Done in Late-Stage Study

Carbylan Therapeutics Reports Top-Line Results From COR1.1 Clinical Trial of Hydros-TA in Patients With OA of the Knee PALO ALTO, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) — Carbylan Therapeutics (NASDAQ:CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced top-line results from COR1.1, its first Phase III trial […]

Read More »

Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a €210m Fund including GSK and Johnson & Johnson Innovation

LONDON, GENEVA and JERSEY, February 2, 2016 /PRNewswire/ — Medicxi Ventures comprises all of the existing life sciences team, portfolio company investments and life sciences funds of Index Ventures GSK and Johnson & Johnson Innovation expand their commitment to the asset-centric approach Index Ventures technology practice remains unchanged Medicxi Ventures, a new venture capital firm […]

Read More »

Edward P. Nathan, PhD joins PulseCX as Chief Creative Officer

PulseCX announced today that Ed Nathan has joined the company as Executive Vice President, Chief Creative Officer.

Read More »

CDC expected to declare end to Chipotle’s E.coli outbreak as soon as Monday: WSJ

The E. coli outbreak that affected dozens of Chipotle Mexican Grill customers in nine states last year is expected to be declared over as soon as Monday, the Wall Street Journal reported, citing people familiar with the government’s investigation. Investigators have not been able to pinpoint the ingredient responsible for the contamination, the Journal said. […]

Read More »

After a Troubling 2015, Avalanche Biotech Marries Gene Therapy Firm for a Fresh Start

Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger – Combined Scientific, Financial and Human Resources Will Support Robust Gene Therapy Pipeline Companies to Host Conference Call Today at 8:00 a.m. ET/ 5:00 a.m. PT MENLO PARK, Calif. and PARIS, Feb. 01, 2016 (GLOBE NEWSWIRE) — Avalanche Biotechnologies, Inc. (“Avalanche”) (Nasdaq:AAVL) and Annapurna Therapeutics SAS (“Annapurna”), […]

Read More »

Drugmaker Abbott Snaps Up Alere for $5.8 Billion

ABBOTT PARK, Ill. – Waltham, Mass.-based Alere Inc. (ABT)’s stock is up more than 45 percent following news of its acquisition by Chicago-based Abbott Laboratories (ABT) this morning. Alere’s stock is trading at $54.01 per share. Up $16.81 in pre-market sales. Abbott announced this morning it was acquiring Alere Inc. for $5.8 billion in an […]

Read More »

Eisai Company Coughs Up $280 Million for Exclusive Rights to HUYA Bioscience’s HBI-8000

Tokyo, Japan-based Eisai Co., Ltd.(ESALF.PK) announced today that it had inked an exclusive license agreement with HUYA Bioscience International for HBI-8000. The deal covers rights to the compound in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore. HYUA had headquarters in China, with offices in the U.S., Japan, South Korea and eight locations […]

Read More »

FDA warns India’s IPCA Labs on manufacturing lapses at three plants

Drugmaker IPCA Laboratories Ltd said the U.S. Food and Drug Administration issued it a warning letter outlining manufacturing quality lapses observed at three of its Indian factories, pushing its shares down as much as 16 percent. The letter concerns the company’s finished-drug plants at Piparia in western India, and Indore in central India, as well […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom